Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.

被引：2
|
作者：
Mobasher, Mehrdad
Huang, Jane
Elstrom, Rebecca L.
Elhamy, Mostafa
Bernaards, Coen
Hallek, Michael J.
Hillmen, Peter
Kater, Arnon Philip
Kipps, Thomas J.
Seymour, John Francis
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Cologne, D-50931 Cologne, Germany
[3] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps7120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7120
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Voorhees, Peter M.
    Iida, Shinsuke
    Cole, Craig
    Quach, Hang
    Pothacamury, Rajvineeth
    Bueno, Orlando
    Lee, Shane
    Rosenberg, Tanya
    Talati, Chetasi
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S47 - S48
  • [42] Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first- line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial
    Hu, X.
    Wang, B.
    Zhang, J.
    Wang, Z.
    Sun, T.
    Wang, S.
    Teng, Y.
    Yan, M.
    Wang, X.
    Jiang, Z.
    Cai, L.
    Pan, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S354 - S354
  • [43] A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.
    Mateos, Maria-Victoria
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Hong, Wan-Jen
    Cooper, Scott
    Yu, Yao
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Karve, Sudeep
    Coppola, Sheryl
    Maciag, Paulo Cesar
    Bueno, Orlando
    Arriola, Emma Louise
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Follows, George
    Burke, John M.
    Grosicki, Sebastian
    Chen, Christine
    Sanna, Alessandro
    Roeker, Lindsey Elizabeth
    Yi, Shuhua
    Munir, Talha
    de la Cruz, Fatima
    Ferrant, Emmanuelle
    Matrai, Zoltan
    Ghia, Paolo
    Jurczak, Wojciech
    Bosch, Francesc
    Hill, Marisa E.
    Wang, Denise
    Guntur, Ananya
    Leow, Ching Ching
    Sharman, Jeff Porter
    Barr, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [46] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
    San-Miguel, Jesus F.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [48] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Dimopoulos, M. A.
    Hungria, V. T. M.
    Radino, A.
    Delimpasi, S.
    Mikala, G.
    Masszi, T.
    Li, J.
    Capra, M.
    Matsumoto, M.
    Sule, N.
    Li, M.
    McKeown, A.
    He, W.
    Bright, S.
    Currie, B.
    Boyle, J.
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
  • [49] BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
    Sharman, Jeff P.
    Jurczak, Wojciech
    Coombs, Catherine C.
    Hill, Marisa
    Wang, Denise
    Ku, Nora C.
    Guntur, Ananya
    Shahda, Safi
    Leow, Ching Ching
    Ghia, Paolo
    Mato, Anthony R.
    BLOOD, 2021, 138 : 3736 - +
  • [50] DAC plus CAG Compared with the Standard 3+7 Regimen for Induction of the Medically Fit Elderly Acute Myeloid Leukemia: An Open-Label, Multicenter, Randomized, Phase III Trial
    Liu, Miaomiao
    Zhang, Yu
    Zheng, Weiyang
    Liu, Qifa
    BLOOD, 2020, 136
12345